Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_46b9de8f8ed70ab1ffc6c24d8c83edd5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_93e8f3f0e161df3d09d4b9a837a21e23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9787cb93dfe501a7ae052043ae06d72c |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 |
filingDate |
2012-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a195c81c6888709b00206335e9046ee5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e5e8db72bb7e1f21a47979575d59678 |
publicationDate |
2013-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2013068371-A1 |
titleOfInvention |
Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists |
abstract |
This invention relates to formulations to improve the bioavailability of the CB-1 antagonist compound in dogs through the use of a soft chewable dosage form. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021213024-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3878436-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017194415-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10117831-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9314478-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11633361-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015042596-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11471437-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021180603-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9808010-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020257333-A1 |
priorityDate |
2011-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |